SOLICITATION NOTICE
66 -- Purchase of a Odyssey CLx Infrared Imaging System
- Notice Date
- 2/10/2015
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC52523-61
- Archive Date
- 3/12/2015
- Point of Contact
- KATHY D. ELLIOTT, Phone: 240-276-5570, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
ELLIOTTK@MAIL.NIH.GOV, ninans@mail.nih.gov
(ELLIOTTK@MAIL.NIH.GOV, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Genome Integrity (LGI) plans to procure on a sole source basis a Odyssey CLx Infrared Imaging System from Li-Cor, Inc., 4647 Superior Street, Lincoln, NE 68504-1395. This acquisition will be processed in accordance with simplified acquisition procedures in FAR Part 13.106 (b)(1). The North American Industry Classification System code is 334516 the business size standard is 500. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be 90 days from date of award. It has been determined that there is no opportunity to acquire green products or services under this contract. This purchase will provide for the supply and on-site installation of an Odyssey CLx Infrared Imaging System. The system will come standard with a laptop. In total, the system will include: (i) Odyssey CLx Infrared Imager (ii) Odyssey CLx Accessory Pack (iii) Image Studio In-Cell Western Analysis Key (iv) In-Cell Western Software Training (v) Image Studio Software One User License (vi) Installation & Training (vii) Odyssey CLx Protocols Manual and (viii) Laptop Computer System. The Laboratory of Genome Integrity (LGI) was established by the National Cancer Institute (NCI) in 2011. The laboratory is a major contributor to the fields of DNA damage and repair as it pertains to cancer biology. As part of the ongoing and planned experiments in the laboratory, there is a need for high-quality detection systems to quantitatively assess the levels of proteins during the cellular response to DNA damage. Typical proteins measurements are performed using qualitative, enyme-based approaches (traditional western blotting). Since the laboratory allows for students, post-doctoral fellows and visiting scientists to perform high quality basic and translational research in cancer biology using state of the art methods in molecular biology, LGI wishes to purchase the Odyssey CLx Infrared Imaging System (9140-01L). The Odyssey system is a powerful detector of multiple biological molecules (e.g., proteins, nucleic acids). Unlike traditional imaging methods, such as western blotting, the Odyssey Imager utilizes two separate solid-state lasers to detect infrared and near infrared dye-labeled conjugates. Infrared or near infrared detection systems have significantly lower background than chemiluminescence or visible light based imaging methods. Because concentrations of proteins that need to be detected vary over a wide range, analysis of western blots by traditional methods may be difficult and weak signals may be masked by high background. The Odyssey Imager provides a broad linear dynamic range to accurately detect strong and weak bands on the same blot thereby bypassing the need of multiple exposures needed when using film. This feature is essential to NCI/LGI experiments which typically involves proteins that are expressed at extremely low levels. The laboratory uses a film-based and enzyme-based approach to protein detection (western blotting). This procurement will provide LGI with an instrument that not only provides a quantitative measurement of protein levels (as stated above), but also delivers an added benefit of detection and quantitation of two targets on the same blot simultaneously. For many of the experiments, NCI profiles 4-6 different target proteins. Using antibodies tagged with HRP (horseradish peroxidase) as a detection method, we have to identify one target protein at a time. After each detection, we have to strip the first target antibody before reusing the blot for detection of another protein. This process also removes some of the membrane bound target protein. Because a blot can be stripped maximally 2-3 times, we have to generate multiple blots to obtain high quality images for all our target proteins. Thus the ability to detect two target proteins simultaneously saves time and even if blot stripping removes some of the target protein the detection of weak signals with low background using the Odyssey detection system becomes feasible. The Laboratory of Genome Integrity requires the purchase of hardware and software to quantitatively image proteins using infrared-based and non-film and non-enzymatic approaches using the Odyssey CLx Infrared Imaging System. LI-COR is the only known company that can provide the hardware and software to perform these services. The procurement in question has a number of features not available from other companies. These include: Hardware Specifications: 1. Simultaneous, two-channel detection is possible for multiplex sample analysis and/or normalization. -This is an important feature for detection of multiple proteins on a single blot. 2. For each channel a dedicated and optimized laser and detection system is provided. -The laser provides an improved method for protein detection over previous generations of the instrument which were camera based. 3. Two infrared, solid state diode lasers emitting at 685 nm +5 nm and 785 nm +5 nm, respectively is the means of excitation of the fluorescent labels. - The use of the infrared spectrum provides for sensitivity equal to or better than chemiluminescence. 4. Detection of the fluorescent dyes must be in the (710 nm - 730 nm) to (810 nm - 830 nm) ranges for the 700 and 800 channels. -This is in order to obtain a high signal-to-noise ratio 5. Linear dynamic range of the detection system must be at least 5 orders of magnitude. - This allows detection of strong and weak bands on the same western blot. 6. Laser/Microscope is integrated into a precision scanning mechanism capable of scanning at resolutions of 21 - 337 μm. 7. The system must have a minimal footprint to save lab space. -The Odyssey CLx Infrared Imaging System has a compact Analysis Software Specifications: Image data is available for viewing in a minimum of three modes - colored overlay, colored single channel and single channel gray scale. - These three methods will allow for a maximum amount of flexibility and detailed data analysis. Other important and unique features of the Odyssey CLx Infrared Imaging System: 1. Use of the infrared spectrum provides higher sensitivity than chemioluminescence due to decreased auto fluorescence and light scatter (i.e. background). 2. Bypass the use of film (an expensive and non-reusable commodity). This allows NCI to avoid the use of dark rooms and image processors harboring toxic chemicals (an expensive and hazardous process). 3. The Odyssey system provides a direct detection method that is much more quantitative than the non-linear enzymatic amplification used in traditional chemiluminescence. 4. Stability of infrared dye-labeled conjugates allows detection for months under proper membrane storage conditions. 5. The Odyssey Imager is used for multiple applications besides western blot analysis. These applications include EMSAs or gel shift assays, protein arrays, in-cell western assays, on-cell western assays, in vivo imaging, coomassie protein gel documentation, DNA gel documentation and tissue section analysis. Li-Cor, Inc. is the original manufacturer of the Odyssey CLx Infrared Imaging System. Due to the nature and complexity of these instruments, as well as the proprietary nature of the hardware and software, Li-Cor, Inc. is the only known contractor that can provide original parts and updated software that are essential for the operation of this system. This is not a solicitation for competitive quotations. However, if any interested parties, especially small businesses, believe they can meet the above requirement, they may submit a statement of capabilities or quote which will be considered by the agency. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. A copy of the capability statement/quote must be received in the NCI Office of Acquisition on or before 11:00 AM EST on February 25 2015. All questions must be in writing and can be faxed (240) 276-5401 or emailed to Kathy Elliott, Contract Specialist at Elliottk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification on Sam.gov, www.sam.gov. No collect calls will be accepted. Please reference solicitation number N02RC52523-61 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC52523-61/listing.html)
- Place of Performance
- Address: NIH / National Cancer Institute, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03638530-W 20150212/150210235008-8de09cd6632400737550767288e85e00 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |